Peptide profile
MOTS-c
Mitochondrial-encoded peptide for glucose control
Compare MOTS-c with other peptides →Summary
A tiny protein from your cells' powerhouses. It helps your body use sugar and energy.
- Typical dose
- 5-10mg Daily
- Route
- Subcutaneous
- Cycle length
- 30-60 days
- Evidence
- Anecdotal
Mechanism
How it works
MOTS-c acts like a text message from your mitochondria to your cell's nucleus — it reports energy status and triggers metabolic adjustments.
MOTS-c is a mitochondrial-derived peptide encoded in 12S rRNA that activates AMPK, improving insulin sensitivity and metabolic flexibility.
Reported in research
Benefits
- Helps your body use sugar better
- Helps your body burn energy faster
- Helps stop weight gain as you get older
- Helps you exercise longer without getting tired
Context, not a prescription
Dosing
- Typical range
- 5-10mg Daily (Subcutaneous)
- Cycle length
- 30-60 days
Safety
Side effects & contraindications
Possible side effects
- Injection site redness
- Mild nausea
- Temporary fatigue
- Headache
- Dizziness
- Flushing
Contraindications
- Pregnancy or breastfeeding
- Severe hypoglycemia
- Known hypersensitivity
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Your body uses sugar better, burns energy faster, and loses fat.
How it works
MOTS-c is like a text message. Your cell powerhouses send it to the cell's brain. It says how much energy you have and asks for changes.
It goes into the control center of your cells. There it tells your body how to use sugar and energy.
What to expect
You may notice changes in your energy use in 2 to 4 weeks.
- Weeks 1-2: Your body starts using energy a little better.
- Weeks 3-4: Your body uses sugar better.
- Weeks 6-8: You slowly lose fat and can exercise longer.
Good to know
- Start with a smaller amount (5mg)
- Check your blood sugar
- Take breaks between using it
Staying safe
- Red skin where you got the shot
- Feeling a little sick to your stomach
- Feeling tired for a short time
Avoid if you have:
- Moms who are pregnant or breastfeeding
- People whose blood sugar drops very low
- People allergic to it
Mechanism of action
MOTS-c is a mitochondrial-derived peptide encoded in 12S rRNA that activates AMPK, improving insulin sensitivity and metabolic flexibility.
Enters nucleus to regulate gene expression for metabolic adaptation and glucose homeostasis.
Pharmacodynamics
Metabolic effects within 2-4 weeks.
Improved insulin sensitivity, increased metabolic rate, reduced fat mass.
Timeline
- Weeks 1-2: Improved metabolic markers.
- Weeks 3-4: Enhanced insulin sensitivity.
- Weeks 6-8: Progressive fat loss and endurance.
Comparisons
- MOTS-c — effectiveness Emerging, safety Emerging, cost $$, Medium to use
- Metformin — effectiveness High, safety Good, cost $, Easy to use
Adverse effects
Common:
- Injection site redness
- Mild nausea
- Temporary fatigue
Rare:
- Headache
- Dizziness
- Flushing
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Severe hypoglycemia
- Known hypersensitivity
- Start with lower dose (5mg)
- Monitor blood glucose
- Cycle with breaks
Qué hace
Tu cuerpo utiliza mejor el azúcar, quema energía más rápido y pierde grasa.
Cómo funciona
MOTS-c es como un mensaje de texto. Las centrales energéticas de tus células lo envían al 'cerebro' de la célula. Indica cuánta energía tienes y solicita ajustes.
Llega al centro de control de tus células. Allí le indica a tu cuerpo cómo utilizar el azúcar y la energía.
Qué esperar
Puedes notar cambios en tu uso de energía en 2 a 4 semanas.
- Semanas 1-2: Tu cuerpo comienza a utilizar la energía un poco mejor.
- Semanas 3-4: Tu cuerpo utiliza mejor el azúcar.
- Semanas 6-8: Pierdes grasa lentamente y puedes ejercitarte más tiempo.
Bueno saber
- Comenzar con una dosis menor (5 mg)
- Revisar tu azúcar en sangre
- Tomar descansos entre ciclos de uso
Manteniéndose seguro
- Enrojecimiento en la zona de la inyección
- Sentir un poco de náuseas
- Sentirse cansado por un corto tiempo
Evitar si tienes:
- Mujeres embarazadas o en lactancia
- Personas con niveles muy bajos de azúcar en sangre
- Personas alérgicas a este péptido
Mecanismo de acción
MOTS-c es un péptido derivado de mitocondrias codificado en 12S rRNA que activa AMPK, mejorando la sensibilidad a la insulina y la flexibilidad metabólica.
Ingresa al núcleo para regular la expresión génica adaptativa y la homeostasis de la glucosa.
Farmacodinamia
Efectos metabólicos en 2-4 semanas.
Mejora de la sensibilidad a la insulina, aumento de la tasa metabólica y reducción de la masa grasa.
Cronología
- Semanas 1-2: Mejora de los marcadores metabólicos.
- Semanas 3-4: Mayor sensibilidad a la insulina.
- Semanas 6-8: Pérdida de grasa progresiva y mejora de la resistencia.
Comparaciones
- MOTS-c — efectividad Emergente, seguridad Emergente, costo $$, Media de usar
- Metformina — efectividad Alta, seguridad Buena, costo $, Fácil de usar
Efectos adversos
Comunes:
- Enrojecimiento en el sitio de inyección
- Náuseas leves
- Fatiga temporal
Raros:
- Dolor de cabeza
- Mareos
- Enrojecimiento
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Hipoglucemia severa
- Hipersensibilidad conocida
- Comenzar con dosis baja (5 mg)
- Monitorear la glucosa en sangre
- Realizar ciclos con pausas
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 30-60 days
FAQ
Common questions
Is MOTS-c naturally occurring?
Yes, it is encoded in the mitochondrial genome.
Does MOTS-c help with type 2 diabetes?
Animal studies show improved glucose tolerance; human research is ongoing.
What is the evidence level?
This compound is classified as Anecdotal. Evidence relies primarily on self-reported user experiences. Controlled studies are lacking.
Research
Research & sources
Current evidence for MOTS-c is rated as Anecdotal. No controlled clinical research is available.
- 1. MOTS-c and metabolism (2015) — DOI:10.1016/j.cmet.2015.02.009
- 2. Mitochondrial peptides review (2021) — DOI:10.1038/s41580-020-00323-5
- 3. MOTS-c and metabolism (2015)
- 4. Mitochondrial peptides review (2021)